Rochester, Minn.-based Mayo Clinic has partnered with a 3D imaging startup to collaborate on artificial intelligence analysis technology.JelloX Biotech entered into a know-how agreement with Mayo Clinic to validate the company's 3D pathology imaging technology with AI for spatial analysis used in precision cancer treatment.'Our goal is to provide researchers and clinicians with more precise diagnostic tools and to support pharmaceutical companies in their quest to develop new drugs to match patients with the right treatment at the right time,' JelloX founder and CEO Yen-Yin Lin, PhD, said in a July 31 statement.The startup participated in the Mayo Clinic and Arizona State University Alliance for Health Care MedTech Accelerator.

总部位于明尼苏达州罗切斯特的梅奥诊所与一家3D成像初创公司合作，在人工智能分析技术方面进行合作。JelloX Biotech与Mayo Clinic签订了专有技术协议，以验证该公司的3D病理成像技术与AI，用于精确癌症治疗中的空间分析。”JelloX创始人兼首席执行官Yen Yin Lin博士在7月31日的一份声明中表示，我们的目标是为研究人员和临床医生提供更精确的诊断工具，并支持制药公司寻求开发新药，以便在正确的时间为患者提供正确的治疗。这家初创公司参与了梅奥诊所和亚利桑那州立大学医疗保健医学技术加速器联盟。

The health system has a financial stake in the technology..

卫生系统在这项技术中具有财务利益。。